It's been a difficult year for Rigel Pharmaceuticals and it just got tougher for 30 of the company's employees, since Rigel decided to restructure its operations after fostamatinib failed earlier this year in three Phase III rheumatoid arthritis clinical trials.
The South San Francisco-based company's stock is trading for less than half of its 2013 peak of $7.53 per share,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
